Sci Rep 2021 Mar 4;11(1):5122. Epub 2021 Mar 4.
Division of Endocrinology, Diabetes and Metabolism, Department of Endocrinology, University Hospital of Basel, Petersgraben 4, 4031, Basel, Switzerland.
While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term. In a large cohort of including 40 men and 60 women, we studied the long-term impact of prolactinoma treatment on bone mineral density (BMD) in men versus women, assessed adverse effects of a primary surgical or medical approach, and evaluated data for risk factors for impaired BMD at last follow-up using multivariate regression analyses. Median duration of follow-up was 79 months (range 13-408 months). Read More